Alterola Biotech Financials

ABTI

Source SEC Filings (10-K/10-Q) Data as of Sep 30, 2024 Currency USD FYE March

This page shows Alterola Biotech (ABTI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ABTI FY2024 2026-07-18

FY2024 shows a balance sheet defined by vanishing assets, with liquidity pressure overwhelming any evidence of operating scale.

From FY2023 to FY2024, assets nearly vanished, falling from $12.0M to $3.7K. Because liabilities still exceeded $1.3M, equity flipped back negative and near-term coverage fell to just 0.003x.

An earlier valid period already showed financing dependence: operating cash outflow of $1.3M was offset mainly by $1.2M of financing inflow, so cash needs were being met externally rather than from operations.

Some figures from recent filings were inconsistent and were omitted from this summary.

Financial Health Signals

Financial health score pending refresh

We are recalculating Alterola Biotech's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

N/A

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$3K

YoY-70.1%

10Y CAGR-11.8%

Alterola Biotech held $3K in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

1.38B

YoY+71.3%

5Y CAGR+64.4%

10Y CAGR+28.2%

Alterola Biotech had 1.38B shares outstanding in fiscal year 2024. This represents an increase of 71.3% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

ABTI Income Statement

Metric	FY24	FY23	FY23	FY20	FY19	FY18
Revenue	N/A	N/A	N/A	$60K	$0	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$182K-46.7%	$341K	N/A	N/A	N/A
SG&A Expenses	N/A	$68K-27.3%	$93K+1764.1%	$5K+856.0%	$523+49.9%	$349
Operating Income	N/A	-$2.0M+68.6%	-$6.5M	N/A	N/A	-$123K
Interest Expense	N/A	N/A	N/A	N/A	$249-97.6%	$11K
Income Tax	N/A	N/A	N/A	$82K	N/A	$18K
Net Income	N/A	-$2.1M-503.8%	-$343K	N/A	N/A	-$113K
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Revenue	$0	$0	N/A	N/A	$0	$0	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$17K-11.3%	$19K	N/A	$3K	$0	$0	N/A	N/A
SG&A Expenses	$24K-44.7%	$43K	N/A	N/A	$24K+275.8%	$6K	N/A	-$28K
Operating Income	-$477K+30.1%	-$683K	N/A	N/A	-$123K+79.0%	-$585K	N/A	-$541K
Interest Expense	$337K	N/A	N/A	N/A	$337K	N/A	N/A	N/A
Income Tax	$0	$0	N/A	N/A	$0	N/A	N/A	N/A
Net Income	-$799K-22.1%	-$655K	N/A	N/A	-$123K+72.5%	-$447K	N/A	-$535K
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0.00

ABTI Balance Sheet

Metric	FY24	FY23	FY23	FY20	FY19	FY18
Total Assets	$4K-100.0%	$12.0M-0.4%	$12.1M+79063.9%	$15K+3.6%	$15K-70.9%	$51K
Current Assets	$4K-92.1%	$46K-48.9%	$91K+493.9%	$15K+3.6%	$15K-70.9%	$51K
Cash & Equivalents	$3K-70.1%	$9K-77.8%	$40K	$0	$0	$0
Inventory	$1K+1.9%	$990	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.3M-41.7%	$2.3M-82.2%	$12.8M+3696.2%	$338K+55.7%	$217K+104.5%	$106K
Current Liabilities	$1.3M-37.4%	$2.1M+74.9%	$1.2M+259.8%	$338K+55.7%	$217K+151.8%	$86K
Long-Term Debt	N/A	N/A	N/A	N/A	$0-100.0%	$20K
Total Equity	-$1.3M-113.6%	$9.8M+1385.9%	-$759K-134.9%	-$323K-59.4%	-$203K-264.8%	-$56K
Retained Earnings	-$12.4M-23.6%	-$10.0M-113.1%	-$4.7M-285.7%	-$1.2M-25.8%	-$971K-125.7%	-$430K

Metric	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Total Assets	$1.4M+39.9%	$975K+26523.7%	$4K+2.1%	$4K-99.3%	$497K-96.1%	$12.7M+5.4%	$12.0M-1.3%	$12.2M
Current Assets	$1.1M+60.4%	$715K+19427.0%	$4K+2.1%	$4K-98.2%	$197K-14.7%	$231K+399.2%	$46K-75.9%	$192K
Cash & Equivalents	$83K-88.4%	$714K+26812.7%	$3K+3.1%	$3K-71.7%	$9K-75.1%	$37K+311.1%	$9K-30.6%	$13K
Inventory	$1K+5.7%	$1K+0.2%	$1K-0.6%	$1K+4.1%	$975-3.4%	$1K+1.9%	$990+2.4%	$967
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$3.6M+48.2%	$2.4M+83.0%	$1.3M-1.9%	$1.4M-46.1%	$2.5M+7.9%	$2.3M+2.1%	$2.3M+15.8%	$2.0M
Current Liabilities	$3.6M+48.2%	$2.4M+83.0%	$1.3M-1.9%	$1.4M-46.1%	$2.5M+7.9%	$2.3M+9.6%	$2.1M+16.9%	$1.8M
Long-Term Debt	N/A	N/A	N/A	N/A	$20K	N/A	N/A	N/A
Total Equity	-$2.1M-49.4%	-$1.4M-3.5%	-$1.3M+1.9%	-$1.4M+33.0%	-$2.0M-119.9%	$10.2M+4.1%	$9.8M-4.6%	$10.2M
Retained Earnings	-$13.7M-5.3%	-$13.0M-4.6%	-$12.4M+0.2%	-$12.4M-19.3%	-$10.4M-1.3%	-$10.3M-2.5%	-$10.0M-5.1%	-$9.6M

ABTI Cash Flow Statement

Metric	FY24	FY23	FY23	FY20	FY19	FY18
Operating Cash Flow	N/A	-$1.3M-3048.0%	$44K+188.7%	-$50K	$0+100.0%	-$20K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	-$140K	N/A	$0	$0	$0
Financing Cash Flow	N/A	$1.2M+12501.2%	-$10K-119.3%	$50K	$0	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Operating Cash Flow	-$861K-315.4%	-$207K	N/A	N/A	-$508K-263.6%	$311K+306.2%	-$151K+81.0%	-$793K
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$60K	$0	N/A	N/A	$202K+221.0%	-$167K-37.2%	-$122K	N/A
Financing Cash Flow	$400K-56.7%	$923K	N/A	N/A	$114K+396.0%	-$39K-136.5%	$106K-86.7%	$796K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	$0	N/A	N/A	N/A	$0

ABTI Financial Ratios

Metric	FY24	FY23	FY23	FY20	FY19	FY18
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-21.2%	N/A	N/A	N/A	N/A
Return on Assets	N/A	-17.2%-14.3pp	-2.8%	N/A	N/A	-222.8%
Current Ratio	0.00-0.0	0.02-0.1	0.07+0.0	0.05-0.0	0.07-0.5	0.59
Debt-to-Equity	N/A	0.23	N/A	N/A	N/A	N/A
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	-4.4%	N/A	-5.2%
Return on Assets	-58.6%+8.6pp	-67.1%	N/A	N/A	-24.8%-21.3pp	-3.5%	N/A	-4.4%
Current Ratio	0.32+0.0	0.29+0.3	0.000.0	0.00-0.1	0.08-0.0	0.10+0.1	0.02-0.1	0.11
Debt-to-Equity	N/A	N/A	N/A	N/A	N/A	0.230.0	0.23+0.0	0.19
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$1.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.00), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Canaquest Medica CANQF

$296K

Hempamericana HMPQ

$292K

Indoor Harvest INQD

$321K

Arev Life Sciences Global Corp AREVF

$318K

Lowell Farms LOWLF

$309K

Frequently Asked Questions

What are Alterola Biotech's total assets?

Alterola Biotech (ABTI) had $4K in total assets as of fiscal year 2024, including both current and long-term assets.

How many shares does Alterola Biotech have outstanding?

Alterola Biotech (ABTI) had 1.38B shares outstanding as of fiscal year 2024.

What is Alterola Biotech's current ratio?

Alterola Biotech (ABTI) had a current ratio of 0.00 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.

Why is Alterola Biotech's debt-to-equity ratio negative or not reported?

Alterola Biotech (ABTI) has negative shareholder equity of -$1.3M as of fiscal year 2024, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.